SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)1

Atara Biotherapeutics, Inc.
(Name of Issuer)
Common Stock, \$0.0001 par value
(Title of Class of Securities)
046513107
(CUSIP Number)
December 31, 2014
Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which this Schedule is Filed: [] Rule 13d-1(b) [] Rule 13d-1(c) [X] Rule 13d-1(d)
securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 046513107

1.	NAME OF REPORTING PERSON						
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) (VOLUNTARY)						
	Domain Partners VIII, L.P.						
	,						
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)			(a)	[X]		
				(b)			
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				Delaware		
		5.	SOLE VOTING POWER	2,141,542 sh	ares o		
NUMBER OF SHARES				Common Stock *			
BENEFICIALLY OWNED BY		6.	SHARED VOTING POWER	-0			
EACH REPORTING		7.	SOLE DISPOSITIVE POWER	2,141,542 sh	ares of		
	PERSON WITH:			Common S	Stock *		
		8.	SHARED DISPOSITIVE POWER		-0-		
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING			2,141,542 shares of			
	PERSON				Common Stock *		
10.	. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN				[]		
	SHARES						
11.	1. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				.6% **		
12.	TYPE OF REPORTING PERS	SON			PN		

^{*} As of December 31, 2014
** Based on 20,212,889 shares of Common Stock outstanding as of December 31, 2014

CUSIP No. 046513107

1.	NAME OF REPORTING PERSON					
	I.R.S. IDENTIFICATION NO	O. OF ABOVE	E PERSON (ENTITIES ONLY) (VOLUN	TARY)		
	DP VIII Associates, L.P.					
2.	CHECK THE APPROPRIAT	E BOX IF A	MEMBER OF A GROUP (see	(a)	[X	
	instructions)			(b)	Ī	
3.	SEC USE ONLY	• •				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION			Delaware		
		5.	SOLE VOTING POWER	15,890 shares of Co	.mm.o.i	
N	UMBER OF SHARES	٥.	SOLE VOTING FOWER	·	Stock ³	
BENEFICIALLY OWNED BY EACH REPORTING		6.	SHARED VOTING POWER			
		7.	SOLE DISPOSITIVE POWER	15,890 shares of Co	ommoi	
	PERSON WITH:				Stock ³	
		8.	SHARED DISPOSITIVE POWER		-0	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			15,890 shares of Common Stock *		
10.	CHECK IF THE AGGREGA SHARES	[]				
11.	PERCENT OF CLASS REPR	0	.1% **			
12.	TYPE OF REPORTING PER	SON			PN	

^{*} As of December 31, 2014
** Based on 20,212,889 shares of Common Stock outstanding as of December 31, 2014

Schedule 13G

Item 1(a) Name of Issuer:

Atara Biotherapeutics, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices:

3620 Bayshore Boulevard Brisbane, CA 94005

Item 2(a) Name of Person Filing:

This statement is being filed by Domain Partners VIII, L.P., a Delaware limited partnership ("Domain VIII"), and DP VIII Associates, L.P., a Delaware limited partnership ("DP VIII A") (together, the "Reporting Persons").

Item 2(b) Address of Principal Business Office:

One Palmer Square Princeton, NJ 08542

Item 2(c) Place of Organization:

Domain VIII: Delaware DP VIII A: Delaware

Item 2(d) Title of Class of Securities:

Common Stock, \$0.0001 par value

Item 2(e) CUSIP Number:

046513107

Item 3 Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):

Not applicable.

Item 4 Ownership.

(a) through The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by (c): reference.

Item 5 Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent

Company:

Not applicable.

Item 8 Identification and Classification of Members of the Group:

See Exhibit 2.

Item 9 Notice of Dissolution of Group:

Not applicable.

Item 10 Certification:

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Dated: February 3, 2015

DOMAIN PARTNERS VIII, L.P.

By:One Palmer Square Associates VIII, L.L.C., General Partner

By:/s/ Kathleen K. Schoemaker

Managing Member

DP VIII ASSOCIATES, L.P.

By:One Palmer Square Associates VIII, L.L.C., General Partner

By:/s/ Kathleen K. Schoemaker

Managing Member

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: February 3, 2015

DOMAIN PARTNERS VIII, L.P.

By:One Palmer Square Associates VIII, L.L.C., General Partner

By:/s/ Kathleen K. Schoemaker

Managing Member

DP VIII ASSOCIATES, L.P.

By:One Palmer Square Associates VIII, L.L.C., General Partner

By:/s/ Kathleen K. Schoemaker

Managing Member

Identification and Classification of Members of the Group

Domain Partners VIII, L.P. and DP VIII Associates, L.P. are filing this statement on Schedule 13G as a group.

Domain Partners VIII, L.P. is a Delaware limited partnership. Its sole general partner is One Palmer Square Associates VIII, L.L.C., a Delaware limited liability company.

DP VIII Associates, L.P. is a Delaware limited partnership. Its sole general partner is One Palmer Square Associates VIII, L.L.C., a Delaware limited liability company.